

Journal of Hepatology Revised Submission Checklist

This form must be completed and submitted for all revised manuscripts. Without this form the manuscript will be returned to the corresponding author for completion.

Corresponding Author:	Dr. Christoph J. Binder or Dr. Tim Hendriks
Manuscript Number:	JHEPAT-D-21-01774

Below, provide the page number(s) or figure legend(s) where the information can be located. Please make sure that all the information requested below is present in the manuscript.

1) Submission

- a) Title page: COI, Financial support, Authors' contributions, keywords.
- b) Structured abstract and lay summary
- c) All tables and figures included, numbered correctly, with legends (p value and statistical test)
- d) Supplementary data included in a single, separate word file
- e) A detailed point by point response to reviewers comments and changes highlighted in text
- f) All authors to complete and upload an ICMJE conflict of interest form.
- g) Graphical abstract

Y / N
Y / N
Y / N
Y / N
Y / N
Y / N
Y / N
Y / N

Completed, or reported on page(s) or figure legend(s):

2) Materials and methods

- a) Completed the CTAT form for all reagents and resource to be added to supplementary material
- b) Identify the source and authentication of cell lines
- c) Identify animal species, number of animals used, strain, sex and age.
- d) For animal studies include a statement of compliance with ethical regulations and identify the committee(s) approving the experiments.
- e) For qPCR data provide information according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines

completed
completed
See CTAT form and Figure legends
CTAT form / Supplementary file p. 3
CTAT form / Supplementary file p. 7-8

3) Human subjects

- a) Identify the committee(s) approving the study protocol.
- b) Include a statement confirming that informed consent was obtained from all subjects.

Supplementary file p. 18-19
Supplementary file p. 18-19

- c) For randomized studies report the clinical trial registration number (at ClinicalTrials.gov or equivalent).

Not applicable

- d) For phase II and III randomized controlled trials:

- I. Please refer to the CONSORT statement and submit the CONSORT checklist with your submission.
- II. Include all version of the study protocol and statistical plan (to be published as supplementary information)

Not applicable

Not applicable

- e) Identify the inclusion/exclusion criteria in the selection process for the patients included in the study

Not applicable / Suppl. file page 18-19

4) Statistics

- a) State what statistical tests were completed and why

Suppl. file page 19 / Figure legends

- b) Explain the sample size and how this size provides an adequate power to detect a pre-specified effect size.

Supplementary file p. 3

5) Data deposition (Provide accession codes for deposited data)

- a) When using public databases:

- I. Identify the source and include a valid link
- II. When using databases that require permission, include a statement confirming that permission was obtained

Not applicable

Not applicable

- b) Data deposition in a public repository is mandatory for:

- I. Protein, DNA and RNA sequences
- II. Microarray data

To be provided if manuscript is accepted

Deposition is strongly recommended for many other datasets for which structured public repositories exist